Sana biotechnology appoints accomplished drug developer dhaval patel, m.d., ph.d., as executive vice president and chief scientific officer

Seattle, aug. 26, 2024 (globe newswire) -- sana biotechnology, inc. (nasdaq: sana), a company focused on changing the possible for patients through engineered cells, today announced the appointment of dhaval patel, m.d., ph.d., as executive vice president and chief scientific officer.

SANA Ratings Summary

SANA Quant Ranking